As we expected, Vitrolife had a hard time living up to the high set expectations for Q2. Sales came in lower than our forecast, mainly due to lower-than-expected sales in the time-lapse and ART equipment business units. The Q2 result witnessed of continued high cost control, however, and profitability was in line with our expectations. The impact on the share price has been significant, but we believe that the market’s reaction was warranted.